Pillar Pacific Capital Management LLC decreased its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 3.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,730 shares of the biopharmaceutical company’s stock after selling 520 shares during the period. Pillar Pacific Capital Management LLC’s holdings in Alexion Pharmaceuticals were worth $1,639,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the business. Boltwood Capital Management bought a new position in shares of Alexion Pharmaceuticals during the 2nd quarter valued at about $921,000. Private Trust Co. NA boosted its position in shares of Alexion Pharmaceuticals by 3.6% during the 2nd quarter. Private Trust Co. NA now owns 16,054 shares of the biopharmaceutical company’s stock valued at $2,102,000 after purchasing an additional 560 shares in the last quarter. Swedbank boosted its position in shares of Alexion Pharmaceuticals by 95.5% during the 2nd quarter. Swedbank now owns 1,429,397 shares of the biopharmaceutical company’s stock valued at $187,222,000 after purchasing an additional 698,096 shares in the last quarter. DNB Asset Management AS boosted its position in shares of Alexion Pharmaceuticals by 33.5% during the 2nd quarter. DNB Asset Management AS now owns 45,269 shares of the biopharmaceutical company’s stock valued at $5,929,000 after purchasing an additional 11,362 shares in the last quarter. Finally, Crossmark Global Holdings Inc. boosted its position in shares of Alexion Pharmaceuticals by 3.4% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 16,863 shares of the biopharmaceutical company’s stock valued at $2,209,000 after purchasing an additional 548 shares in the last quarter. 94.68% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Alexion Pharmaceuticals stock traded up $0.46 during trading on Thursday, reaching $107.09. The company’s stock had a trading volume of 13,179 shares, compared to its average volume of 1,801,932. The stock has a market capitalization of $24.02 billion, a P/E ratio of 15.08, a price-to-earnings-growth ratio of 1.03 and a beta of 1.65. Alexion Pharmaceuticals, Inc. has a one year low of $92.56 and a one year high of $141.86. The company has a current ratio of 3.98, a quick ratio of 3.45 and a debt-to-equity ratio of 0.25. The stock has a 50-day moving average price of $102.27 and a two-hundred day moving average price of $115.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the previous year, the business posted $2.02 EPS. The company’s quarterly revenue was up 23.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.41 EPS for the current fiscal year.
Several equities analysts have recently weighed in on the stock. Leerink Swann set a $157.00 price objective on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, September 3rd. William Blair assumed coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 26th. They issued an “outperform” rating and a $146.00 target price for the company. Bank of America assumed coverage on shares of Alexion Pharmaceuticals in a report on Thursday, October 17th. They issued a “buy” rating for the company. Citigroup set a $150.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 30th. Finally, Morgan Stanley decreased their target price on shares of Alexion Pharmaceuticals from $177.00 to $170.00 and set an “overweight” rating for the company in a report on Friday, October 11th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the company. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $159.00.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Recommended Story: What is the price-sales ratio?
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.